| Project/Area Number |
26461237
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
富野 康日己 順天堂大学, 医学部, 名誉教授 (60130077)
鈴木 祐介 順天堂大学, 医学(系)研究科(研究院), 教授 (70372935)
|
|---|
| Research Collaborator |
ARAI Satoko
MIYAZAKI Toru
TAKAHATA Akiko
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | IgA腎症 / AIM / マクロファージ / 起炎性 / gddY |
|---|
| Outline of Final Research Achievements |
Recent papers revealed that apoptosis inhibitor of macrophage (AIM; also called CD5L), plays important roles in arthrosclerosis, obesity-associated autoimmunity, and clearance in hepatocellular carcinoma. Furthermore, the most recent investigated features are that AIM is involved in renal tissue repair, and pathology of acute kidney injury [AKI]. In this study, we found that AIM contributes to the phlogogenesity of IgAN.
|
